Outlook Therapeutics Appoints Faisal G. Sukhtian As Chairman Of The Board

Outlook Therapeutics Inc. is a biopharmaceutical firm that received EU and UK regulatory approval for its first ophthalmic bevacizumab treatment of wet age-related macular degeneration (wet AMD). The company announced that Faisal G. Sukhtian would take over as the Chair of its Board of Directors immediately. Mr. Sukhtian has taken charge as Randy Thurman while retaining the Board position as Lead Independent Director.

Mr. Sukhtian said in a statement, “On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude to Randy for his extraordinary leadership and unwavering commitment. Under his guidance, Outlook Therapeutics has evolved from a preclinical biotech to a company preparing to launch its first product. Randy’s decades of experience in the biopharmaceutical industry, strategic insight, and mentorship have been invaluable in shaping the Company’s trajectory. I am personally grateful for his continued role as Lead Independent Director, and I look forward to continuing to work closely with him as we embark on this exciting next phase.”

He also commented,  “I am honoured to take on the role of Chairman and deeply appreciate the trust placed in me by the Board. This is a pivotal year for Outlook Therapeutics as we prepare to launch LYTENAVA™ in the EU and the UK, bringing an important new treatment option to patients in those markets. At the same time, we remain focused on completing a timely FDA resubmission in the United States and advancing the development of our asset to expand its scope and reach to patients worldwide.

I look forward to working with our exceptional management team and Board to execute on our vision to deliver this important treatment to patients.”

“I look forward to continuing as a member of the Outlook Therapeutics Board as Lead Independent Director and working toward our goal of getting LYTENAVA™ approved and launched worldwide. Were it not for Faisal and GMS Ventures and Investments and their financial leadership, Outlook Therapeutics would not be where it is today - on the verge of an opportunity to greatly improve the health of patients around the world suffering from neovascular age-related macular degeneration. Improving human health has been the focus of my long career in life sciences,” commented Mr. Thurman.